Evidence map›Paper›PMID 41367424›Full record

ArticleFrontiers in microbiology2025

Identification of multi-drug resistant

Yaru Zhi, Dongmei Yan, Qinfang Tang, Lihua Xiao, Aiting Cai, Mingzhong Sun, Hongmei Chen, Yungang Wang, Qingping Fu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Revisiting the Fight AgainstAntibiotics (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yaru Zhi *Department of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Dongmei Yan *Department of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Qinfang TangDepartment of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Lihua XiaoDepartment of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Aiting CaiDepartment of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Mingzhong SunDepartment of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Hongmei ChenDepartment of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Yungang WangDepartment of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Qingping FuDepartment of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Carbapenem-resistant Methods: The treatment of bacterial infections may improve with the development of phage therapy and phage-antibiotic combination therapy. Here, we reported a novel phage YZ2 that has a double-stranded DNA genome of 40,181 bp with 37.93% GC content. A total of 46 open reading frames (ORFs) and no virulence or antimicrobial resistance genes were annotated in the genome of phage YZ2. Phage YZ2 is a novel member of the Results: The Discussion: Moreover, compared with the use of phage or polymyxin B alone, the combined use of phage YZ2 and polymyxin B can significantly increased the survival rate of

Indexed as

Acinetobacter baumanniibiological characteristicsgenome analysismultidrug resistantphage therapyphage YZ2

Identifiers

PMID41367424
PMCPMC12682814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.